Escape Tab n / 120mg film about 40 pc

$7.89

Escape Tab n / 120mg film about 40 pc

Quantity:

SKU: 1954088832 Categories: , , Tag:

Description

Composition
Active substance:
1 tablet contains: bismuth tripotassium dicitratobismuthate – 300,00 mg, based on bismuth oxide – 120.00 mg.
Excipients:
Corn Starch – 54.22 mg, povidone (polyvinyl pyrrolidone of middle, Povidone K 25) – 42.00 mg, polacrilin (polacrilin potassium) – 20.00 mg magnesium stearate – 3, 78 mg.
Sheath: AquaPolish® P white 019.49 MS [Hydroxypropyl methylcellulose (E 464) – 7.80 mg; hydroxypropylcellulose (E 463) – 1.30 mg; stearic acid (E 570) – 0.91 mg; talc (E 553b) – 1,30 mg; polyethylene glycol – 0.39 mg; titanium dioxide (E171) – 1.30 mg] – 13.00 mg.
Description:
Round biconvex tablets, film-coated white or almost white, low odor of ammonia on the fracture white or nearly white.
Product form:
Tablets, film-coated, 120 mg.
At 10 or 14 tablets in blisters of PVC film and aluminum foil printed patent. 2, 4, 8 or 16 contour cell packages together with instructions for use placed in a pile of cardboard.
Contraindications
– increased individual sensitivity to the drug; – pregnancy; – the period of breast-feeding; – reception of preparations containing bismuth; – Chronic renal failure; – Children under 4 years old.
Dosage
120 mg
Indications
– functional dyspepsia not associated with organic diseases of the gastrointestinal tract; – chronic gastritis and gastroduodenitis in the acute phase, including those associated with Helicobacter pylori; – gastric ulcer and duodenal ulcer in the acute phase, including those associated with Helicobacter pylori; – Irritable bowel syndrome occurs predominantly with symptoms of diarrhea.
Interaction with other drugs
Within half an hour before and after drug administration is not suitable for use within other drugs, as well as meal and liquid, in particular antacids, milk, fruit and fruit juices. This is due to the fact that they, while ingestion may affect the efficiency of bismuth tripotassium dicitrate.
The drug reduces the absorption of tetracyclines.
Preparation is not used in conjunction with other pharmaceutical preparations containing bismuth, as bismuth simultaneous use of several drugs increases the risk of side effects, including the risk of encephalopathy.
Overdose
In applying the drug in doses tens of times higher than recommended, or long-term use of excessive doses of the drug may develop poisoning bismuth.
Symptoms: dyspepsia, rash, inflammation of the oral mucosa, in the form of darkening characteristic blue lines on the gums; during prolonged use at doses exceeding recommended possibly kidney function.
These symptoms are completely reversible remove the drug.
Treatment: cpetsificheskogo no antidote. If overdose shown gastric lavage, ehnterosorbentov and symptomatic therapy aimed at maintaining renal function. In case of overdose, also shows the assignment of laxatives. Subsequently, treatment should be symptomatic. In the case of impaired renal function, accompanied by high levels of bismuth in plasma, it is possible to enter the complexing agents – dimerkaptoyantarnuyu and dimercapto-propanesulfonic acid. With the development of severe renal impairment indicated hemodialysis.
pharmachologic effect
Pharmacological group:
Antiulcer agent, an antiseptic and astringent intestines.
Pharmacodynamics:
Gastroprotective and antiulcer agent with antibacterial activity against Helicobacter pylori. Also has anti-inflammatory and astringent.
In the acidic environment of the stomach precipitated insoluble bismuth oxychloride and citrate chelated compound formed from a proteinaceous substrate a protective film on the surface of ulcers and erosions. Thus preparation forms a protective layer, which for a long period of time protects the affected areas of the mucosa from the effects of aggressive factors. By increasing the synthesis of prostaglandin E, mucus secretion and bicarbonate, stimulates activity of cytoprotective mechanisms increases resistance mucosa of the gastrointestinal tract to the action of pepsin, hydrochloric acid, enzymes and bile salts. Leads to the accumulation of epidermal growth factor in the defect area. Reduces the activity of pepsin and pepsinogen.
Pharmacokinetics:
Practically not absorbed from the gastrointestinal tract. It appears mainly faeces. A minor amount of bismuth, received by the plasma is excreted by the kidneys.
Pregnancy and breast-feeding
Bismuth tripotassium dicitratobismuthate contraindicated for use in pregnant women. If necessary, use during lactation should stop breastfeeding.
Conditions of supply of pharmacies
Without recipe.
side effects
The following adverse events reported during the application of bismuth tripotassium dicitrate, distributed over occurrence frequency according to the following gradation: very often (> 1/10); common (> 1/100, 1/1000, 1/10 000,
Gastro-intestinal tract: often – fecal staining black; infrequently – nausea, vomiting, diarrhea or constipation.
Allergic reactions: seldom – skin rash, itching; very rarely – anaphylactic reactions.
From the nervous system: very rarely – long-term use at high doses – encephalopathy is associated with the accumulation of bismuth in the CNS.
Side effects are reversible and quickly disappear after drug withdrawal.
special instructions
The drug should not be used more than 8 weeks. It is not recommended during treatment exceed the daily dose for adults and children. The period of treatment should not be applied other preparations containing bismuth (see. See “The interaction with other drugs”). Upon completion of a course of drug treatment at the recommended doses of active principle concentration in the blood plasma of not more than 3 – 58 g / l, and the toxicity is observed only at concentrations above 100 g / l.
In applying bismuth tripotassium dicitrate possible staining of feces in a dark color due to the formation of bismuth sulphide. Sometimes there is a slight darkening of the tongue. During treatment is not recommended alcohol intake.
Effect on the ability to drive mechanisms and
Data on the effect of the drug Eskeyp® tablets, film-coated on the ability to drive and there are no mechanisms.
Storage conditions
Store at a temperature not higher than 25 ° C. Keep out of the reach of children.
Dosing and Administration
Inside. The duration of treatment and the dose determined by the physician individually for each patient, depending on the nature of the disease.
Adults and children over 12 years of drug prescribed 1 tablet 4 times a day for 30 minutes before a meal (breakfast, lunch, dinner) and at night, or 2 tablets 2 times a day 30 minutes before meals (breakfast, dinner).
Children aged 8 to 12 years: 1 tablet 2 times a day for 30 minutes before a meal (breakfast and dinner).
Children aged from 4 to 8 years administered in a dose of 8 mg / kg / day; depending on the body weight of the child prescribed 1-2 tablets a day (or in 1-2 daily administration). Thus, the daily dose should be closest to the calculated dose (8 mg / kg / day).
Tablets are taken 30 minutes before eating, with a small amount of water.
Tablet is recommended to swallow whole without chewing or crushing, drinking plenty of water. Not recommended drink milk tablets. The duration of treatment typically is from 4 to 8 weeks. After receiving the drug is not recommended to take medicines containing bismuth (e.g., Vikalin, Vikair) for 2 months.
For eradication of Helicobacter pylori advisable to use Bismuth tripotassium dicitrate in combination with antibacterial agents having Helicobacter activity.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

OTISIFARM

There are no reviews yet.

Add your review